BREATHE-Xchange

CALENDAR

Improving Outcomes in COPD: An Evidence-Based Approach to Disease Management
 

This program will provide an overview of the burden and progression of COPD, discuss the current rationale supporting evidence-based treatment, and present key clinical data for Perforomist® (formoterol fumarate) Inhalation Solution in the treatment of COPD.

 

Presenter: Antonio R. Anzueto, MD

Professor of Medicine
University of Texas Health Science Center at San Antonio
Section Chief, Pulmonary/Critical Care
South Texas Veterans Health Care System
San Antonio, Texas

Wednesday, October 7, 2009

1:30 pm ET | 12:30 pm CT
11:30 am MT | 10:30 am PT

Friday, October 9, 2009

4:00 pm ET | 3:00 pm CT
2:00 pm MT | 1:00 pm PT

Tuesday, October 13, 2009

3:30 pm ET | 2:30 pm CT
1:30 pm MT | 12:30 pm PT

Wednesday, October 21, 2009

2:00 pm ET | 1:00 pm CT
12:00 pm MT | 11:00 am PT

 
 
Optimizing Patient Care in COPD: A Case-Based Perspective
 

This program will discuss strategies for the management of COPD and analyze key efficacy and safety data supporting the role of Perforomist Solution in the COPD treatment paradigm. Clinical profiles of patient candidates who may benefit from this treatment will also be presented.

 

Presenter: Sanjay Sethi, MD

Professor of Medicine
Chief, Division of Pulmonary, Critical Care, and Sleep Medicine
University at Buffalo, State University of New York
Buffalo, New York

Friday, October 16, 2009

12:30 pm ET | 11:30 am CT
10:30 am MT | 9:30 am PT

Monday, October 19, 2009

4:00 pm ET | 3:00 pm CT
2:00 pm MT | 1:00 pm PT

Tuesday, October 20, 2009

1:30 pm ET | 12:30 pm CT
11:30 am MT | 10:30 am PT

Wednesday, October 28, 2009

1:00 pm ET | 12:00 pm CT
11:00 am MT | 10:00 am PT

 
 
Redefining the Standard of Care in COPD: What is the Role of Nebulization?
 

This program will discuss the relevant factors that influence the selection of nebulized therapy in the treatment of COPD, including disease severity, patient characteristics, clinical setting, and patient preference.

 

Presenter: Donald P. Tashkin, MD

Distinguished Professor of Medicine
Medical Director, Pulmonary Function Laboratory
David Geffen School of Medicine at UCLA
Los Angeles, California

Monday, October 12, 2009

1:30 pm ET | 12:30 pm CT
11:30 am MT | 10:30 am PT

Monday, October 26, 2009

3:30 pm ET | 2:30 pm CT
1:30 pm MT | 12:30 pm PT

Tuesday, October 27, 2009

12:30 pm ET | 11:30 am CT
10:30 am MT | 9:30 am PT

Friday, October 30, 2009

4:00 pm ET | 3:00 pm CT
2:00 pm MT | 1:00 pm PT

 
 
Indications

Perforomist® (formoterol fumarate) Inhalation Solution is a long-acting beta2-agonist indicated for long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema.

Important Safety Information

There is an increased risk of asthma-related death with long-acting beta2-agonists, the class of drugs to which Perforomist® Inhalation Solution belongs. Perforomist® Inhalation Solution is not indicated for asthma or in deteriorating COPD. Perforomist® Inhalation Solution should not be used to treat acute symptoms, which should be treated with an inhaled short-acting beta2-agonist.

Click here for full prescribing information for Perforomist® Solution, including boxed warning.

Click here for additional important safety information.

Spiriva® HandiHaler® is indicated for the long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.

Spiriva® HandiHaler® is not indicated for the initial treatment of acute episodes of bronchospasm; ie, rescue therapy.

Perforomist® is a registered trademark of Dey, L.P.
U.S. Patent Nos. 6,814,953 and 6,667,344
DEY® is a registered trademark of Dey, L.P.
© 2009 Dey, L.P. All rights reserved.

Spiriva® and HandiHaler® are registered trademarks and are used under license from Boehringer Ingelheim GmbH.